Cargando…

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination

BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV) is highly immunogenic and efficacious in adults ≥50 years of age. We evaluated (1) long-term immunogenicity of an initial 2-dose RZV schedule, by following up adults vaccinated at ≥60 years of age and by modeling, and (2) immunogenicity of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hastie, Andrew, Catteau, Grégory, Enemuo, Adaora, Mrkvan, Tomas, Salaun, Bruno, Volpe, Stephanie, Smetana, Jan, Rombo, Lars, Schwarz, Tino, Pauksens, Karlis, Hervé, Caroline, Bastidas, Adriana, Schuind, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672743/ https://www.ncbi.nlm.nih.gov/pubmed/32502272 http://dx.doi.org/10.1093/infdis/jiaa300

Ejemplares similares

2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling
por: Bastidas, Adriana, et al.
Publicado: (2019)

Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults
por: Pauksens, Karlis, et al.
Publicado: (2017)

Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
por: Schwarz, Tino F., et al.
Publicado: (2018)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
por: Boutry, Céline, et al.
Publicado: (2021)

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
por: Cunningham, Anthony L, et al.
Publicado: (2018)

1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial
por: Mrkvan, Tomas, et al.
Publicado: (2018)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine
por: Grupping, Katrijn, et al.
Publicado: (2017)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial
por: Rümke, Hans C, et al.
Publicado: (2013)

Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer
por: Boeckh, Michael J, et al.
Publicado: (2020)

Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults
por: Assantachai, Prasert, et al.
Publicado: (2023)

Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
por: Dagnew, Alemnew F., et al.
Publicado: (2021)

Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine
por: Pauksens, Karlis
Publicado: (2013)

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
por: Chen, Wilbur H., et al.
Publicado: (2014)

Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children
por: Claeys, Carine, et al.
Publicado: (2019)

Trends in Hospitalizations With Primary Varicella and Herpes Zoster During the Prevaricella and Initial Postvaricella and Herpes Zoster Vaccine Eras, Connecticut, 1994–2012
por: Humes, Elizabeth A., et al.
Publicado: (2015)

Effects of Prior Influenza Exposure on Immunogenicity of Influenza Vaccine
por: Cao, Jia-Qian, et al.
Publicado: (2020)

8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)
por: Boutry, Céline, et al.
Publicado: (2020)

Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial
por: Schuind, Anne, et al.
Publicado: (2015)

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
por: Madan, Anuradha, et al.
Publicado: (2016)

Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
por: López-Fauqued, Marta, et al.
Publicado: (2021)

Herpes Zoster and Recurrent Herpes Zoster
por: Shiraki, Kimiyasu, et al.
Publicado: (2017)

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
por: Oostvogels, Lidia, et al.
Publicado: (2019)

A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia
por: Carpenter, Christopher F, et al.
Publicado: (2019)

Increased Incidence of Giant Cell Arteritis After Introduction of a Live Varicella Zoster Virus Vaccine
por: Agger, William A, et al.
Publicado: (2020)

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
por: Curran, Desmond, et al.
Publicado: (2017)

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
por: Ulaszewska, Marta, et al.
Publicado: (2023)

37. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine (RZV) in Immunocompromised Populations: an Overview of 6 Trials
por: Fauqued, Marta Lopez, et al.
Publicado: (2020)

HBV Seroprotection and Anamnestic Response to Booster Vaccination in Pediatric Cancer Survivors
por: Suwanpakdee, Detchvijitr, et al.
Publicado: (2021)

Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis
por: Vasconcelos, Zanair Soares, et al.
Publicado: (2023)

Optimal Timing of Zoster Vaccination After Shingles: A Prospective Study of the Immunogenicity and Safety of Live Zoster Vaccine
por: Lee, Eunyoung, et al.
Publicado: (2018)

Humoral and Cellular Immunogenicity of Zoster Vaccine within One Year after Herpes Zoster
por: Lee, Eunyoung, et al.
Publicado: (2017)

Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination
por: Jongkees, Marlou J, et al.
Publicado: (2022)

Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique
por: de Deus, Nilsa, et al.
Publicado: (2020)

Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study
por: Berkowitz, Elchonon M., et al.
Publicado: (2015)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant
por: Desjardins, Michaël, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_48pou8aqri9m0oikgqcg44jmvb